LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday, November 19, 2025, at 07:00 a.m. CET.
In conjunction to the report, investors, analysts, and media are invited to an audiocast with teleconference (in English) on November 19, at 3:00 p.m. CET, where Cantargia's CEO Hilde Steineger, CMO Wolfram Dempke, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.
If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: https://cantargia.events.inderes.com/q3-report-2025.
If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/cantargia/q3-report-2025/dial-in.
The webcast will also be available on demand on Cantargia's corporate website: www.cantargia.com.
For further information, please contact
Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: info@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
Attachments
Invitation to the Presentation of Cantargia’s Interim Report January-September 2025
SOURCE: Cantargia
View the original press release on ACCESS Newswire
